With a recent pruritus approval in the books and several more potential launches coming in the next year and a half, Switzerland’s Vifor Pharma is …

Amid reports that COVID-19 antibody treatments from Regeneron and Eli Lilly lose their effectiveness against the omicron variant, GlaxoSmithKline and Vir Biotechnology said on Tuesday …

The future of ViiV Healthcare’s HIV business is injectable. By 2026, the majority-GlaxoSmithKline-owned joint venture expects long-acting regimens to generate around £2 billion ($2.65 billion) …

GlaxoSmithKline isn’t just making changes with its U.S. operations. The company is now exploring a new location for its global headquarters amid a historic business …

Many companies have shifted their way of working amid COVID-19. Adjusting to how work is done these days, GlaxoSmithKline is downsizing its office footprint in …

GlaxoSmithKline’s long-acting HIV drug cabotegravir is already challenging market leaders as part of an approved treatment regimen. Now, the medicine is a step closer to …

As officials in Washington weigh contentious drug-pricing measures, there’s even more evidence that pharma companies are worried about potential reform. In an open letter to …